An Open-Label Phase I Follow-up Study on Patients with HCV-induced Cirrhosis who received treatment with PRI-724 to observe Safety and Efficacy
- Conditions
- Hepatitis C virus-induced cirrhosis
- Registration Number
- JPRN-UMIN000014891
- Lead Sponsor
- Tokyo metropolitan Komagome Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 18
Not provided
(1)Female patients who are pregnant or suspected to be pregnant. (2) Male patients who do not consent to using reliable contraception methods for 12 weeks after the end of infusion of PRI-724 in 1101 study. (3)Patients contraindicated for liver biopsy. Unless the patients were found to be contraindicated for liver biopsy after receiving PRI-724 in 1101 study. (4) Patients who were enrolled in other clinical study other than 1101-study within 30 days prior the consent. (5) 1101-study termination with follow-up failure due to pass-away or other reasons. (6) Patients judged by investigators ineligible due to seriousness of patients condition.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.